补髓生血颗粒对慢性再生障碍性贫血患者临床与相关粘附分子作用机制的实验研究
|
摘要
为了探讨补髓生血颗粒对慢性再障患者(CAA)的作用机制。本研究采用单盲法将60例慢性再障患者随机分为补髓生血颗粒组和再障生血片对照组，对其临床疗效、骨髓活检组织和骨髓基质细胞细胞粘附分子和粘附能力进行了观察分析和实验研究。
采用免疫荧光法检测慢性再障患者治疗前后骨髓基质细胞(BMSC)血小板内皮细胞粘附分子(PECAM／CD31)、淋巴细胞归巢受体(HCAM／CD44)、细胞间粘附分子(ICAM／CD54)、血管细胞粘附分子(VCAM／CD106)抗原水平表达。采用MTT方法检测其骨髓基质细胞对正常骨髓造血细胞和再障患者细胞的粘附能力。
结果显示：1、补髓生血颗粒治疗CAA疗效优于再障生血片，阳虚型疗效优于阴虚型，且阳虚型患者骨髓基质细胞粘附分子水平较阴虚型患者更易恢复。2、补髓生血颗粒可改善骨髓诸类组织含量异常病理状态，使造血组织面积明显增加，脂肪组织明显减少，小血管数量增加，恢复骨髓的造血功能。3、两组患者治疗前PECAM／CD31、HCAM／CD44、ICAM／CD54、VCAM／CD106粘附分子水平明显低于正常对照组，治疗后两组患者PECAM／CD31、HCAM／CD44、ICAM／CD54、VCAM／D106抗原水平都有不同程度的升高，并且补髓生血颗粒对PECAM／CD31、VCAM／CD106抗原水平的提高方面优于再障生血片对照组。4、CAA BMSC对骨髓造血细胞粘附能力明显下降，治疗后两组患者其粘附能力提高，且补髓生血颗粒组优于再障生血片对照组。
结论：补髓生血颗粒治疗CAA，疗效优于再障生血片，进一步证实了“阳虚易治，阴虚难调”的理论。补髓生血颗粒可改善骨髓诸类组织含量异常病理状态，恢复骨髓的造血功能。慢性再障患者BMSC的粘附分子PECAM／CD31、HCAM／CD44、ICAM／CD54、VCAM／CD106的表达水平下降，且对骨髓造血细胞粘附能力下降，补髓生血颗粒可提高PECAM／CD31、HCAM／CD44、ICAM／CD54、VCAM／CD106粘附分子的表达和提高CAA BMSC对骨髓造血细胞粘附能力，从而促进慢性再障患者的骨髓造血。
For discussing the mechanism of marrow-supplementing and blood-engendering granule to chronic aplastic anemia (CAA) patients, this study employed single blind procedure to divide sixty CAA patients into marrow- supplementing and blood-engendering granule group and ZaiZhang ShengXue tablet group randomly and made observation and experiment on its clinical curative effect, live bone marrow examination constitution, bone marrow stromal cell (BMSC) adhesion molecule and adhesion function.
This experiment employed iminumofluorescence method to examine the expression level of plalete endothelial cell adhesion molecule (PECAM/CD31), lymphocyte homing receptor(HCAM/CD44), intercellular adhesion molecule ( ICAM/CD54 ) , vascular cell adhesion molecule ( VCAM/ CD106) antigen in BMSC of CAA patients before and after treatment. This experiment used MMT method to test the adhesion function of BMSC in CAA patients to the normal and CAA patients bone hemopoietic cells.
Result: 1. The effect of marrow-supplementing and blood-engendering granule to CAA was superior to that of ZaiZhang ShengXue tablet. In the marrow-supplementing -and blood-engendering granule group, its curative effect was superior in Yang deficiency type to that in Yin deficiency type, and the recovery of adhesion function of BMSC in Yang deficiency type was easier than that in Yin deficiency type. 2. Marrow-supplementing and blood-engendering granule can ameliorate pathologic status in many tissues in bone marrow, increase the area of hematopoietic tissue, redcuce adipose tissue, raise the amount of small vessels, and recover hematopoietic function in bone marrow. 3. The content of PECAM/CD31, HCAM/CD44,
ICAM/CD54, VCAM/CD106 adhesion molecule in patients of the two groups were lower than that in the normal controlled group markedly before treatment. After treatment, the content of PECAM/CD31 , HCAM/CD44 , ICAM/CD54 , VCAM/CD106 antigen in two groups had all been advanced in different digree, and the advancement of PECAM/CD31, VCAM/CD106 antigen in group group. 4.The adhesion function of BMSC in CAA patients to bone hemopoietic cells descended markedly, after treatment the adhesion function in two groups was enhanced, and the enhancement in marrow-supplementing and blood-engendering granule group was superior to that in ZaiZhang ShengXue tablet group.
Conclusion: The effect of marrow-supplementing and blood-engendering granule to CAA is superior to that of ZaiZhang ShengXue tablet. Our experiments further testified the theory 'Yin deficiency is easy to treat, but Yang deficiency is difficult to treat.' Marrow-supplementing and blood-engendering granule can ameliorate pathologic status in many tissues in bone marrow, and recover hematopoietic function in bone marrow.The expression level of adhesion molecule PECAM/CD31 , HCAM/CD44, ICAM/CD54 , VCAM/CD106 in CAA patients declined, and its adhesion function to bone hemopoietic cells also descended. Marrow-supplementing and blood-engendering granule can enhance expression level of adhesion molecule PECAM/CD31, HCAM /CD44, ICAM/CD54, VCAM/CD106 and the adhesion function of CAA BMSC to bone hemopoietic cells, therefore enhance the hemopoietic function of bone marrow.
采用免疫荧光法检测慢性再障患者治疗前后骨髓基质细胞(BMSC)血小板内皮细胞粘附分子(PECAM／CD31)、淋巴细胞归巢受体(HCAM／CD44)、细胞间粘附分子(ICAM／CD54)、血管细胞粘附分子(VCAM／CD106)抗原水平表达。采用MTT方法检测其骨髓基质细胞对正常骨髓造血细胞和再障患者细胞的粘附能力。
结果显示：1、补髓生血颗粒治疗CAA疗效优于再障生血片，阳虚型疗效优于阴虚型，且阳虚型患者骨髓基质细胞粘附分子水平较阴虚型患者更易恢复。2、补髓生血颗粒可改善骨髓诸类组织含量异常病理状态，使造血组织面积明显增加，脂肪组织明显减少，小血管数量增加，恢复骨髓的造血功能。3、两组患者治疗前PECAM／CD31、HCAM／CD44、ICAM／CD54、VCAM／CD106粘附分子水平明显低于正常对照组，治疗后两组患者PECAM／CD31、HCAM／CD44、ICAM／CD54、VCAM／D106抗原水平都有不同程度的升高，并且补髓生血颗粒对PECAM／CD31、VCAM／CD106抗原水平的提高方面优于再障生血片对照组。4、CAA BMSC对骨髓造血细胞粘附能力明显下降，治疗后两组患者其粘附能力提高，且补髓生血颗粒组优于再障生血片对照组。
结论：补髓生血颗粒治疗CAA，疗效优于再障生血片，进一步证实了“阳虚易治，阴虚难调”的理论。补髓生血颗粒可改善骨髓诸类组织含量异常病理状态，恢复骨髓的造血功能。慢性再障患者BMSC的粘附分子PECAM／CD31、HCAM／CD44、ICAM／CD54、VCAM／CD106的表达水平下降，且对骨髓造血细胞粘附能力下降，补髓生血颗粒可提高PECAM／CD31、HCAM／CD44、ICAM／CD54、VCAM／CD106粘附分子的表达和提高CAA BMSC对骨髓造血细胞粘附能力，从而促进慢性再障患者的骨髓造血。
For discussing the mechanism of marrow-supplementing and blood-engendering granule to chronic aplastic anemia (CAA) patients, this study employed single blind procedure to divide sixty CAA patients into marrow- supplementing and blood-engendering granule group and ZaiZhang ShengXue tablet group randomly and made observation and experiment on its clinical curative effect, live bone marrow examination constitution, bone marrow stromal cell (BMSC) adhesion molecule and adhesion function.
This experiment employed iminumofluorescence method to examine the expression level of plalete endothelial cell adhesion molecule (PECAM/CD31), lymphocyte homing receptor(HCAM/CD44), intercellular adhesion molecule ( ICAM/CD54 ) , vascular cell adhesion molecule ( VCAM/ CD106) antigen in BMSC of CAA patients before and after treatment. This experiment used MMT method to test the adhesion function of BMSC in CAA patients to the normal and CAA patients bone hemopoietic cells.
Result: 1. The effect of marrow-supplementing and blood-engendering granule to CAA was superior to that of ZaiZhang ShengXue tablet. In the marrow-supplementing -and blood-engendering granule group, its curative effect was superior in Yang deficiency type to that in Yin deficiency type, and the recovery of adhesion function of BMSC in Yang deficiency type was easier than that in Yin deficiency type. 2. Marrow-supplementing and blood-engendering granule can ameliorate pathologic status in many tissues in bone marrow, increase the area of hematopoietic tissue, redcuce adipose tissue, raise the amount of small vessels, and recover hematopoietic function in bone marrow. 3. The content of PECAM/CD31, HCAM/CD44,
ICAM/CD54, VCAM/CD106 adhesion molecule in patients of the two groups were lower than that in the normal controlled group markedly before treatment. After treatment, the content of PECAM/CD31 , HCAM/CD44 , ICAM/CD54 , VCAM/CD106 antigen in two groups had all been advanced in different digree, and the advancement of PECAM/CD31, VCAM/CD106 antigen in group group. 4.The adhesion function of BMSC in CAA patients to bone hemopoietic cells descended markedly, after treatment the adhesion function in two groups was enhanced, and the enhancement in marrow-supplementing and blood-engendering granule group was superior to that in ZaiZhang ShengXue tablet group.
Conclusion: The effect of marrow-supplementing and blood-engendering granule to CAA is superior to that of ZaiZhang ShengXue tablet. Our experiments further testified the theory 'Yin deficiency is easy to treat, but Yang deficiency is difficult to treat.' Marrow-supplementing and blood-engendering granule can ameliorate pathologic status in many tissues in bone marrow, and recover hematopoietic function in bone marrow.The expression level of adhesion molecule PECAM/CD31 , HCAM/CD44, ICAM/CD54 , VCAM/CD106 in CAA patients declined, and its adhesion function to bone hemopoietic cells also descended. Marrow-supplementing and blood-engendering granule can enhance expression level of adhesion molecule PECAM/CD31, HCAM /CD44, ICAM/CD54, VCAM/CD106 and the adhesion function of CAA BMSC to bone hemopoietic cells, therefore enhance the hemopoietic function of bone marrow.
引文
[1] 杨文华，万增志．戴锡孟，等．补肾活血法治疗再生障碍性贫血机理探讨[J]．天津中医，1993：(4)：22～23
[2] 黄振翘，黄韬，周永明．补肾泻肝方对再生障碍性贫血患者NKa、IL-2和T细胞亚群的影响[J]．中国中医药科技．1995：2(1)：11～13
[3] 邓有安，颜雄仁．杨才明，等．活血化瘀法为主治疗再生障碍性贫血14里疗效分析[J]．中医杂志，1981：(12)：37～39
[4] 黄世林，魏艾红，肖景文，等．再障舌质研究．中国医药学报[J]，1990；5(3)：33～34
[5] 谢波，邓有安．颜雄仁．等．50例再障患者甲皱微循环观察分析[J]．中华血液学杂志：1993，14(4)：197～198
[6] 寇孟诃．再生障碍性贫血“毒入骨髓”病机初探[J]．四川中医，1996：14(10)：8～9
[7] 麻柔，周霭祥，郑金福．慢性再生障碍性贫血患者外周血T淋巴细胞亚群改变与中医分型的关系[J]．中国中西医结合杂志．1992．12(3)：142．
[8] 刘宝文，石伟，张绍蕊．慢性再生障碍性贫血的中医辨证分型与外周血T淋巴细胞亚群、红细胞C3b受体的关系[J]．．中国中西医结合杂志，1992：12(4)：221～222
[9] 孙伟正，曲佳丽，姚洪义，等．慢性再生障碍性贫血中医辨证治疗与免疫骨髓造血细胞关系的研究[J]．中医药信息，1994：11(3)：39
[10] 罗秀素，虞荣喜，郑宝根，等．再生障碍性贫血辨证分型与体外骨髓造血祖细胞类型的关系[J]．中国中西医结合杂志，1992：12(3)：139
[11] 钟达锦．中西医结合治疗再生障碍性贫血46例临床分析[J]．中西医结合杂志，1984：4(11)：679～681
[12] 王介人．再障患者血清微量元素与中医辨证的关系[J]．中医研究，1988；1 (2)：22
[13] 王继亮．再障患者头发微量元素的检测[J]．医学理论与实践杂志，1989： (4)：13
[14] 储榆林，杨天楹．梁骅．再生障碍性贫血中西医结合分型的探讨[J]．中华血液血杂志，1985；6(8)：478～481
[15] 俞亚琴．再生障碍性贫血中医辨证与甲皱微循环关系的研究[J]．辽宁中医
杂志，1996，(1)：145．
[16] 谢波，高丹，袁永强．不同中医证型再生障碍性贫血甲皱微循环异常及与外周血的关系[J]．四川中医，1996，(1)：15．
[17] 展昭民，等．补肾药对再生障碍性贫血骨髓造血祖细胞作用的研究[J]．中医药信息，中医药信息．1989；(1)：23
[18] 苏尔云，等．鸡血藤附方治疗再生障碍性贫血临床观察[J]．中国中西医结合杂志．1997；17(4)：213～215
[19] 周永明，黄振翘，薛志忠，等．健脾补肾活血法治疗再生障碍性贫血的临床研究[J]．上海中医药杂志，1995，(7)：12～14
[20] 孙汉英，董凌莉．刘文励，等．复方活血汤对再生障碍性贫血小鼠骨髓造血细胞粘附分子及细胞周期蛋白表达作用[J]．中国中西医结合杂志，1999；19(2)：100～102
[21] 黄韬，黄振翘．周永明，等．造血与免疫失调治疗的实验研究[J]．中国中西医结合杂志，1998；(18)增刊：189
[22] 黄韬，黄振翘，周永明．等．补肾泻肝方对再生障碍性贫血的疗效与血清sIL-2R关系的研究．上海中医药杂志．1999：(5)：47～48
[23] 周蔼祥．王天恩．杨经敏，等．益肾生血片治疗再生障碍性贫血的实验研究[J]．中国中西医结合杂志．1999，19(3)：170～173
[24] 周永明．程军．薛志忠．等．生血合剂及其拆方对免疫介导再生障碍性贫血小鼠作用的实验研究．上海中医药大学学报．2002：16(1)：56～59
[25] 黄干，祝彼得，张淑慎．人参总皂甙对小鼠血细胞生成的影响[J]．中华血液学杂志，1990；11(2)：66～68
[26] 麻柔，谢仁敷，廖军群，等．成对和单味中药对造血细胞的作用[J]．中西医结合杂志，1984：4(9)：533～535
[27] 第五届全国再生障碍性贫血学术会议纪要[J]．中华血液学杂志．1991：12：161
[28] 李元善，张韬玉．全国首届中西医结合血液病学术会议概况[J]．中西医结合志．1983：3(1)：61～63
[29] 高学敏．中药学．北京：中国医学科技出版社，1990：310，219
[30] 周霭祥，王奎．公殿广．等．人参对人类造血功能影响的实验研究[J]．中国医药学报，1987：2(1)：25～27
[31] 谢仁敷．廖军群．袁淑雯，等．活血化瘀药对骨髓造血的影响[J]．中西医
结合杂志，1988：8(10)：616～617
[32] 谢仁敷，等．补肾活血中药对骨髓造血功能的影响[J]．中国中西医结合杂志，1994：14(增刊)：65
[33] 舒砚君，孙汉英，董凌莉．川芎嗪对免疫介导再生障碍性贫血小鼠骨髓细胞CD34抗原表达的影响[J]．中国中西医结合杂志，1998：18(2)：107～108
[34] 董昆山，王秀琴，董一凡，等．现代临床中药学．北京：中国中医药出版社，1998：471～472
[35] 盖云，高瑞兰．牛泱平等．补益中药对机体免疫功能的调节作用实验研究[J]中国中西医结合杂志，2003：23(9)：680～683
[36] 第七届全国再生障碍性贫血学术会议纪要[J] 中华血液学杂志，1996：17(4)：222
[37] 杨崇礼，邵宗鸿．郑以洲．等．再生障碍性贫血．天津：天津科技翻译出版社2000：10～12
[38] Frichhofen N, et al. Virscsand bonc marrow faillnre[J] Am J Pediatr Hematol Oncol, 1990: 12 (4): 385
[39] Zeldis JB, et al. A regional experience of red cell aplasia [J] Hepatology, 1988; 8(4): 755.
[40] Young NS, et al. Aplastic anemia in the Orient [J] Br J Haematol, 1986; 62(1): 1.
[41] Baranski B, et al. Immune thrombocytopenic purpuraevolyigy into aplastic anemiain associatinon with Epstein-Bayy virus infccfian[J] Ann Intern Med, 1988; 109(9): 695.
[42] Young NS, ParrovirusB19 as a cause of acquired chyonic pure red cell aplasia [J] Semin Haematol, 1988; 25(3): 159.
[43] Scopes J, Daly S, Atkinson R, et al. Aplastic anemia: Evidence for dysfunctional bone marrow progenitor cells and the corrective elect of granulocyte colony-stimulating factor in vitro [J]. Blood, 1996: 87(8): 3179～85.
[44] Asano H, Hotta T, Ichihara M, et al. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes[J]. Leukemia 1994; 8: 833～8.
[45] Sato T, Kim S, Selleri C, et al. Measurement of secondary colony formation
after 5 weeks in long-term cultures in patients with myelodysplastic syndrome[J]. Leukemia 1998; 12: 1187～94.
[46] Mart'nez-Jaramillo G, Sáinchez-Valle E, Gómez-Morales E, et al. Sequential variations in the content of bone marrow colony-forming cells in individual patients with aplastic anemia before aud after immunosuppressive therapy[J]. Hematology 2000; 5: 247～55.
[47] Maciejewski J, Anderson S, Katevas P, Young NS. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure[J]. Br J Haematol 1994; 87: 227～34
[48] Scopes J, Bagnara M, Gondon -Smith EC, et al[J]. Br J Haematol, 1994; 86(2): 427～30
[49] Marsh JCM, et al. In vitro assessment of marrow rstem cell and stromal cell function in aplastic anemia[J]. Br J Haematol, 1991; 78: 258
[50] Sawada K. Proliferation and differentiation of myelodysplastic CD34+ cells[J]. Leuk Lymphoma 1996; 12: 43～51
[51] Mayani H, Baines P, Bowen DT, Jacobs A. In vitro growth of myeloid and erythroid progenitor cells from myeiodysplastic patients in response to recombinant human granulocyte-macropbage colony stimulating factor[J]. Leukemia 1989; 3: 29～32.
[52] Merchav S, Wagemarker G, Souza LM, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulatiou with recombinaut haematopoietic growth factors[J]. Leukelnia 1991; 5: 340～6
[53] Amano Y, Koike K, Nakahata T. Stem cell factor enhances the growth of primitive erythroid progeuitors to a greater extent than interleukin-3 in patients with aplastic anemia[J]. Br J Haematol 1993; 85: 663～669
[54] Gibson FM, Scopes J, Daly S, Ball SE, Gordon-Smith EC. In vitro response of normal and aplastic auemia bone marrow to mast cell growth factor and in combination with granulocyte-macrophage colony-stimulating factor and interleukin-3[J]. Exp Hematol 1994; 22: 302～12.
[55] Mart'nez-Jaramillo G, G6mez-Moralcs E, Mayani H. Effect of recombinant human granulocyte-macrophage colony-stimulatiug factor in long-term marrow
cultures from patients with aplastic anemia[J]. Am J Hematol 1999; 61: 107～14.
[56] Wodnar-Filipowicz A, Chklovskaia E, Manz CY, et al. Effect of Flt3 ligand on in vitro growth and expansion of colonyforming bone marrow cells from patients with aplastic anemia[J], Exp Hematol 1997; 25: 573～81.
[57] Guadalupe Mart'nez-Jaramillo, Eugenia Flores-Figueroa, Elizabeth Sánchez-Valle, et al. Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia[J]. Leukemia Research 2002; 26: 955～963
[58] Callera F, Falcao RP. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anemia [J]. Br J Haematol, 1997(1); 98: 18～20
[59] Callera F, Garcia AB, Falcao RP. Fas-mediated apoptosis with normol express of bcl-2 and p53 in lymphocytes from aplastic anemia[J]. Br J Haematol, 1998; 100(4): 698～703
[60] Craiy B, Hematopoietic cells from mice deficiemfin wild wild-typo P53 are more resistsnt to induction of apoptosis by some agents [J] SThompson Science, 1995; 267: 1459
[61] 奚永志，张双喜，郝秀娟．等．细胞凋亡调控蛋白在骨髓CD_(34)~+造血细胞中的表达[J]．中华医学杂志，1997：77(3)：197～200
[62] Maciejewski JP, Selleri C, Sato J, et al Increased apoptosis in aplastic anemia bone marrow, progenitor cells [J]. Br J Haematol, 1995; 91 (1): 245～52
[63] Horikawa K, Nakakuma H, Kawaguchi T, et al Characterization and partial purification of human marrowy cells capable of initiaing long-term hematpoiesis in vitro[J]. Blood, 1997; 90: 2716
[64] 夏长青．李景斗．储榆林．再生障碍性贫血免疫治疗现状[J]．国外医学 内科学分册．1997；24：338～341
[65] 宋振岚，谢普耀．范成明，等．再生障碍性贫血免疫发病机制的探讨[J]．中华血液学杂志，1996：17[4]：173～175
[66] Viale M ,Merli A,Bacigalupo A. Analysis at the clonal level of T-cell phenotype and functions in severe aplastic anemia patients[J]. Blood, 1991, 81: (6)1268～1274
[67] Nakao S. Immunc mechanism of aplastic anemia [J]. Int J Haematol, 1997, 66 (2): 127～134
[68] Melenhorst J J, Krieken J H, Dreef E, et al. T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anemia[J]. Br J Haematol, 1997;99:517
[69] 夏长青，储榆林．张君奎，等．严重型再生障碍性贫血患者骨髓和外周血HLA-DR~+T细胞的变化及其淋巴细胞造血抑制活性的研究[J]．中华血液学杂志，1997；18[4]：186～189
[70] Melenhorst JJ, Fibbe WE, Struyk L, et al. Analysis of T-cell clonality in bone marrow of patients with acquired aplastic anaemia[J]. Br J Hacematol. 1997, 96: 85～91
[71] 王冠军．再生障碍性贫血病人骨髓及外周血T淋巴细胞亚群与造血抑制的关系[J]．中华内科杂志．1990；13[4]：229～230
[72] Nagasawa T, Hasegawa Y, Shimizu S. et al .Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects[J], Br J Hematol 1998; 101: 242
[73] 夏长青．储榆林．邵宗鸿．等．严重型再生障碍性贫血患者骨髓造血祖细胞集落的形成与免疫抑制治疗疗效的关系[J]．中华血液学杂志．1997；18[11]：542～543
[74] Nistico A.Yaoung ns. Gamma-interferon gone expression in the marrow of patients with aplastic anenmia [J]. Ann intem Med. 1994; 120:463～469
[75] Nakao S, Yamaguchi M, Shiobara S, et al. Interferon-r gene expression in unstimulatated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia[J]. Blood. 1992; 79 2532～2535
[76] 曾风华，沈柏均，时庆，等．再生障碍性贫血忠者骨髓T淋巴细胞的研究[J]．中华血液学杂志，1997：18[11]：542～543
[77] Manz CY, Dietrich PY, Schnuriger V, et al. T-cell receptor β chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia[J]. Blood Cells Mol and Dis, 1997; 23: 110～122
[78] Nimer SD, Ireland P, Meshikinpour AP, et al. An increased HLA DR2 frequency is seen in aplastic anemia patients [J]. Blood, 1994; 84: 923～927
[79] Nakao S, Takamatsu H, Chuhjo T, et al .Identification of a specific HLA class Ⅱ haplo type strongly associated with susceptibility to cyclosporiue-dcpendent aplastic anemia[J]. Blood, 1994; 84: 4257～4261
[80] 张学光，傅晋翔．再生障碍性贫血免疫机制的研究进展[J]．中国免疫学杂
志．2000：16(10)：517～520
[81] Nakao S, Takamatsu H, Yachie A, et al. Establishment of a CD4+ Tcell clone recognizing autologous hematpopietic progenitor cells from a patient with immune-mediated aplastic anemia [J]. Exp Hematol. 1995; 23: 433～438
[82] Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRBl *0405-restrcticted cytotoxicity for hematopoietic cells in a paeent with aplastic anemia[J]. Blood, 1997; 89: 3691～3699
[83] 赵劲秋，王燕婷，邵念贤．等．再生障碍性贫血T细胞亚群及NK细胞活性与疗效的关系[J]．上海免疫学杂志．1996：18[4]：232～234
[84] 郑以州，储榆林．ALG／ATG治疗再生障碍性贫血疗效机制研究进展[J]．国外医学 内科学分册．1997；24[4]：206～208
[85] 邵宗鸿，陈克其．陈桂彬，等．严重型再障患者血清 IL-2、sIL-2R 水平与免疫抑制治疗关系的研究[J]．中华血液学杂志．1997；18[3]：180～182
[86] Koijima S. Hematopoietic growth factors and marrow stroma in aplastic anemia [J]. Int J Hematol. 1998, 68: 19～28.
[87] Stark R, et al Acquired aplastic anemia [J]. Blood, 1995; 85: 645
[88] Fujiwara M. Grenulocyfe colony-stimalating factor and granulocyte [J] Acta Haematol Jpn, 1990; 75: 421
[89] Gibson FM, et al Erythropoietin and platelet production[J]. Br J Haematol, 1995; 91(8):551～561
[90] Stark R, et al. Cytokine gene expression in peripheral bloodmononudear cells during graft-versus-host disease after allogenic bone marrow transplantation[J]. Br J Haematol, 1993;83(11):560～566
[91] Nissen C Wodnar -Filipowicz A, Slanicka-Krieger M, et al[J]. Eur J Haematol, 1995; 55 (6): 255～61.
[92] Holmberg L, Seidel K, Leisenring W, et al Cyclosporin A in aplastic anemia report a workshop[J]. Blood, 1994; 84(11): 3685～90
[93] 刘杰文．齐淑玲．de Wynter E，et al．长期培养的人骨髓基质细胞中有关造血调节的粘附蛋白表达的研究．中华血液学杂志．1997：18[8]：468～469
[94] 陈文杰，朱平．血液分子生物学 第一版 北京：中国医药科技出版社1993：49～51
[95] Radera G, Petrocelli T, Behrend E, et al. Overexpression of the
Integrin-linked kinase promotes anchorage independent cell cycle progression[J]. J Biol Chem 1997; 272(21): 13937～13944
[96] 董凌莉，刘文励，孙汉英，等．川芎嗪对再生障碍性贫血小鼠细胞粘附作用研究[J]．中华血液学杂志，1999；20[4]：178～179
[97] 董爱英，王润田．马立人．20 例再生障碍性贫血的细胞因子和粘附分子的表达分析[J]．中华检验医学杂志，2002；23[5]：156～158
[98]金朝晖，陶英，杨梅如．等．细胞间粘附分子在急性髓系白血病骨髓切片中的表达及临床意义[J]．中国实用内科杂志．2000：20(6)：346～348
[99] Wodnar-Filipowicz A, Yancik S, Moser Y, et al. Levels of soluble stem cell factor in serum of patients with aplastic anemia[J]. Blood 81:3259～3264, 1993.
[100] Nimer SD, Leung DHY, Wolin MJ. Golde DW. Serum stem cell factor levels in patients with aplastic anemia[J]. Int J Hematol 1994: 60: 185～189
[101] Kojima S, Matsuyama T, Kodera Y. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anemia [J]. Br J Haematol, 1997; 99(2):440～446
[102] 傅晋翔．张宏．虞斐 张学光．再生障碍性贫血正负造血生长因子浓度变化及临床意义[J]．中国免疫学杂志．2000：(16) 10：554～557
[103] Ronald L. Paquette , Nicholas C. Hsu , H. Phillip Koeffler. Analysis of c-kit Gene Integrity in Aplastic Anemia|J|. Blood Cells, Molecules, and Diseases 1996; 22 (14): 159～168
[104] 邵宗鸿，陈桂彬．张泓．等．再生障碍性贫血忠者骨髓造血干／祖细胞c-kit受体表达[J]．中华血液学杂志．1999：20 (10)：532～534
[105] Wodnar-Filipowicz A, Ticheili A, Zscbo KM, Speck B, Nissen C. Stem cell factor stimulates the in vitro growth of bone marrow cells from aplastic anemia patients[J]. Blood 1992; 79: 3196～3202
[106] Bagnara GP, Strippoli P, Bonsi L, et al. Effect of stem cell factor on colony growth from acquired and constitutional (Fanconi) aplastic anemia[J]. Blood 1992: 80:382～387
[107] [110] Aiuti A, Webb IJ, Bleul C. et al. The chemokine SDF-1 is a chemoattractant for human CD_(34)~+ hcmatopoictic progenitor cells and provides a new mechanism to explain the mobilization of CD_(34)~+ progenitors to peripheral blood[J].
J Exp Med, 1997,185:111～120
[108] Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor[J]. Science, 1996, 272～276
[109] D'Apuzzo M, Rolink A, Loetscher M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4[J]. Eur J Immunol, 1997, 27: 1788～1794
[110] Sozzani S, Liuni W, Borsatti A, et al. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines[J]. J Immunol, 1997, 159: 1993-2000
[111] Mohle R, Bautz F, Rafii, S, et al. The chemokine receptor CXCR4 is expressed on CD_(34)~+ hematopoietic progenitors and leukemic cells and mediated transendothelial migration induced by stromal cell-derived factor-1[J]. Blood, 1998, 91: 4523～4530
[112] Tsuge I, Kojima S, Matsuoka H, et al Blood cell cytoadhesion molecules[J]. Br J Haematol, 1993; 84(1):137～43
[113] 第七届全国再生障碍性贫血学术会议纪要[J] Chinese Journal of Haematology，April 1996，vol 17．No．4
[114] 张之南主编．血液病诊断及疗效标准．天津：天津科学技术出版社，1991：31～34
[115] 杨天楹主编．造血细胞培养技术．西安：陕西科学技术出版社 1985：147-160
[116] 储榆林．再生障碍性贫血几种常见治疗药物评价[J]．临床血液学杂志，2000：13(3)：139～140
[117] 孙伟正，等．以补肾中药为主治疗再生障碍性贫血215例的生存率及远期疗效分析[J]．中医杂志，1988；29(4)：27
[118] 曲佳丽．黑龙江中医药大学93年博士论文，1993；3
[119] 薄红，刘传瑞．范东明．等．补髓生血颗粒对慢性再生障碍性贫血患者红细胞免疫功能、血清CIC、补体C3的作用[J] 中国中医药科技．1999：6(2)：101
[120] 孙伟正，王样琪，袁斌华．等 应用“补髓生血颗粒”治疗24例慢性再生障碍性贫血骨髓 CD34、CD 10变化规律的分析[J]中医药信息．1994；11(2)：28～30
[121] 朱跃岚．孙伟正．补髓生血胶囊治疗慢性再生障碍性贫血临床研究[J]北京
中医药大学学报，1998：21(5)：48～49
[122] 赵新广，王样麒．朱跃岚，等．补髓生血胶囊对慢性再障患者造血干／祖细胞作用的实验研究[J]中医药信息．1998：(153)：53～55
[123] 孙伟正，罗梅宏．李海霞．等．补髓生血颗粒对慢性再生障碍性贫血患者血清可溶性Fas、肿瘤坏死因子、白细胞介素2表达作用的影响[J] 中医杂志，2001： 42(9)：546～547
[124] 孙伟正．罗梅宏，蒋宁，等．补髓生血颗粒对慢性再生障碍性贫血患者血清Fas、Bcl-2表达作用[J] 中国实验方剂学杂志．2001：7(4)：54～55
[125] 补髓生血颗粒对慢性再生障碍性贫血患者 CD34+、Fas+及CD34+mP53表达细胞影响的实验研究[J] 中医药学报，2001：29(4)：36-37
[126] Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractans: stromal cell-derived factor-1, steel factor, and the bone marrow environment[J]. Blood, 1998, 91 (1): 100～110 al analysis of bone marrow progenitor cell [J]. Blood, 1995, 16(12): 619～622
[127] 李夏新，洪平．曾琼．血小板内皮粘刚因子对脐血造血细胞的影响[J]第一军医大学学报，1999：19(1)：15～17
[128] 金朝辉．骨髓活检塑料包埋技术加强新进展[J]．医学综述．1999，10(5)： 186～188
[129] Verfaillie C, et al. Differentiation of primitive human multipotent hemopoietic progenitors into single lineage clonogenic progenitors is accompanied by alteraions in their interaction with fibronectin [J]. J Exp Med, 1991, 174: 693
[130] Verfaillie C, et al. Direct contct between progenitors and stroma is not requireds for human in vitro hematopoiesis[J]. Blood ,1992, 79: 2821
[131] Quesenberry P J, Crittenden R B, Lowry P, et al In. vivo studies of stromal niches[J]. Blood Cells. 1994, 20: 97
[2] 黄振翘，黄韬，周永明．补肾泻肝方对再生障碍性贫血患者NKa、IL-2和T细胞亚群的影响[J]．中国中医药科技．1995：2(1)：11～13
[3] 邓有安，颜雄仁．杨才明，等．活血化瘀法为主治疗再生障碍性贫血14里疗效分析[J]．中医杂志，1981：(12)：37～39
[4] 黄世林，魏艾红，肖景文，等．再障舌质研究．中国医药学报[J]，1990；5(3)：33～34
[5] 谢波，邓有安．颜雄仁．等．50例再障患者甲皱微循环观察分析[J]．中华血液学杂志：1993，14(4)：197～198
[6] 寇孟诃．再生障碍性贫血“毒入骨髓”病机初探[J]．四川中医，1996：14(10)：8～9
[7] 麻柔，周霭祥，郑金福．慢性再生障碍性贫血患者外周血T淋巴细胞亚群改变与中医分型的关系[J]．中国中西医结合杂志．1992．12(3)：142．
[8] 刘宝文，石伟，张绍蕊．慢性再生障碍性贫血的中医辨证分型与外周血T淋巴细胞亚群、红细胞C3b受体的关系[J]．．中国中西医结合杂志，1992：12(4)：221～222
[9] 孙伟正，曲佳丽，姚洪义，等．慢性再生障碍性贫血中医辨证治疗与免疫骨髓造血细胞关系的研究[J]．中医药信息，1994：11(3)：39
[10] 罗秀素，虞荣喜，郑宝根，等．再生障碍性贫血辨证分型与体外骨髓造血祖细胞类型的关系[J]．中国中西医结合杂志，1992：12(3)：139
[11] 钟达锦．中西医结合治疗再生障碍性贫血46例临床分析[J]．中西医结合杂志，1984：4(11)：679～681
[12] 王介人．再障患者血清微量元素与中医辨证的关系[J]．中医研究，1988；1 (2)：22
[13] 王继亮．再障患者头发微量元素的检测[J]．医学理论与实践杂志，1989： (4)：13
[14] 储榆林，杨天楹．梁骅．再生障碍性贫血中西医结合分型的探讨[J]．中华血液血杂志，1985；6(8)：478～481
[15] 俞亚琴．再生障碍性贫血中医辨证与甲皱微循环关系的研究[J]．辽宁中医
杂志，1996，(1)：145．
[16] 谢波，高丹，袁永强．不同中医证型再生障碍性贫血甲皱微循环异常及与外周血的关系[J]．四川中医，1996，(1)：15．
[17] 展昭民，等．补肾药对再生障碍性贫血骨髓造血祖细胞作用的研究[J]．中医药信息，中医药信息．1989；(1)：23
[18] 苏尔云，等．鸡血藤附方治疗再生障碍性贫血临床观察[J]．中国中西医结合杂志．1997；17(4)：213～215
[19] 周永明，黄振翘，薛志忠，等．健脾补肾活血法治疗再生障碍性贫血的临床研究[J]．上海中医药杂志，1995，(7)：12～14
[20] 孙汉英，董凌莉．刘文励，等．复方活血汤对再生障碍性贫血小鼠骨髓造血细胞粘附分子及细胞周期蛋白表达作用[J]．中国中西医结合杂志，1999；19(2)：100～102
[21] 黄韬，黄振翘．周永明，等．造血与免疫失调治疗的实验研究[J]．中国中西医结合杂志，1998；(18)增刊：189
[22] 黄韬，黄振翘，周永明．等．补肾泻肝方对再生障碍性贫血的疗效与血清sIL-2R关系的研究．上海中医药杂志．1999：(5)：47～48
[23] 周蔼祥．王天恩．杨经敏，等．益肾生血片治疗再生障碍性贫血的实验研究[J]．中国中西医结合杂志．1999，19(3)：170～173
[24] 周永明．程军．薛志忠．等．生血合剂及其拆方对免疫介导再生障碍性贫血小鼠作用的实验研究．上海中医药大学学报．2002：16(1)：56～59
[25] 黄干，祝彼得，张淑慎．人参总皂甙对小鼠血细胞生成的影响[J]．中华血液学杂志，1990；11(2)：66～68
[26] 麻柔，谢仁敷，廖军群，等．成对和单味中药对造血细胞的作用[J]．中西医结合杂志，1984：4(9)：533～535
[27] 第五届全国再生障碍性贫血学术会议纪要[J]．中华血液学杂志．1991：12：161
[28] 李元善，张韬玉．全国首届中西医结合血液病学术会议概况[J]．中西医结合志．1983：3(1)：61～63
[29] 高学敏．中药学．北京：中国医学科技出版社，1990：310，219
[30] 周霭祥，王奎．公殿广．等．人参对人类造血功能影响的实验研究[J]．中国医药学报，1987：2(1)：25～27
[31] 谢仁敷．廖军群．袁淑雯，等．活血化瘀药对骨髓造血的影响[J]．中西医
结合杂志，1988：8(10)：616～617
[32] 谢仁敷，等．补肾活血中药对骨髓造血功能的影响[J]．中国中西医结合杂志，1994：14(增刊)：65
[33] 舒砚君，孙汉英，董凌莉．川芎嗪对免疫介导再生障碍性贫血小鼠骨髓细胞CD34抗原表达的影响[J]．中国中西医结合杂志，1998：18(2)：107～108
[34] 董昆山，王秀琴，董一凡，等．现代临床中药学．北京：中国中医药出版社，1998：471～472
[35] 盖云，高瑞兰．牛泱平等．补益中药对机体免疫功能的调节作用实验研究[J]中国中西医结合杂志，2003：23(9)：680～683
[36] 第七届全国再生障碍性贫血学术会议纪要[J] 中华血液学杂志，1996：17(4)：222
[37] 杨崇礼，邵宗鸿．郑以洲．等．再生障碍性贫血．天津：天津科技翻译出版社2000：10～12
[38] Frichhofen N, et al. Virscsand bonc marrow faillnre[J] Am J Pediatr Hematol Oncol, 1990: 12 (4): 385
[39] Zeldis JB, et al. A regional experience of red cell aplasia [J] Hepatology, 1988; 8(4): 755.
[40] Young NS, et al. Aplastic anemia in the Orient [J] Br J Haematol, 1986; 62(1): 1.
[41] Baranski B, et al. Immune thrombocytopenic purpuraevolyigy into aplastic anemiain associatinon with Epstein-Bayy virus infccfian[J] Ann Intern Med, 1988; 109(9): 695.
[42] Young NS, ParrovirusB19 as a cause of acquired chyonic pure red cell aplasia [J] Semin Haematol, 1988; 25(3): 159.
[43] Scopes J, Daly S, Atkinson R, et al. Aplastic anemia: Evidence for dysfunctional bone marrow progenitor cells and the corrective elect of granulocyte colony-stimulating factor in vitro [J]. Blood, 1996: 87(8): 3179～85.
[44] Asano H, Hotta T, Ichihara M, et al. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes[J]. Leukemia 1994; 8: 833～8.
[45] Sato T, Kim S, Selleri C, et al. Measurement of secondary colony formation
after 5 weeks in long-term cultures in patients with myelodysplastic syndrome[J]. Leukemia 1998; 12: 1187～94.
[46] Mart'nez-Jaramillo G, Sáinchez-Valle E, Gómez-Morales E, et al. Sequential variations in the content of bone marrow colony-forming cells in individual patients with aplastic anemia before aud after immunosuppressive therapy[J]. Hematology 2000; 5: 247～55.
[47] Maciejewski J, Anderson S, Katevas P, Young NS. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure[J]. Br J Haematol 1994; 87: 227～34
[48] Scopes J, Bagnara M, Gondon -Smith EC, et al[J]. Br J Haematol, 1994; 86(2): 427～30
[49] Marsh JCM, et al. In vitro assessment of marrow rstem cell and stromal cell function in aplastic anemia[J]. Br J Haematol, 1991; 78: 258
[50] Sawada K. Proliferation and differentiation of myelodysplastic CD34+ cells[J]. Leuk Lymphoma 1996; 12: 43～51
[51] Mayani H, Baines P, Bowen DT, Jacobs A. In vitro growth of myeloid and erythroid progenitor cells from myeiodysplastic patients in response to recombinant human granulocyte-macropbage colony stimulating factor[J]. Leukemia 1989; 3: 29～32.
[52] Merchav S, Wagemarker G, Souza LM, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulatiou with recombinaut haematopoietic growth factors[J]. Leukelnia 1991; 5: 340～6
[53] Amano Y, Koike K, Nakahata T. Stem cell factor enhances the growth of primitive erythroid progeuitors to a greater extent than interleukin-3 in patients with aplastic anemia[J]. Br J Haematol 1993; 85: 663～669
[54] Gibson FM, Scopes J, Daly S, Ball SE, Gordon-Smith EC. In vitro response of normal and aplastic auemia bone marrow to mast cell growth factor and in combination with granulocyte-macrophage colony-stimulating factor and interleukin-3[J]. Exp Hematol 1994; 22: 302～12.
[55] Mart'nez-Jaramillo G, G6mez-Moralcs E, Mayani H. Effect of recombinant human granulocyte-macrophage colony-stimulatiug factor in long-term marrow
cultures from patients with aplastic anemia[J]. Am J Hematol 1999; 61: 107～14.
[56] Wodnar-Filipowicz A, Chklovskaia E, Manz CY, et al. Effect of Flt3 ligand on in vitro growth and expansion of colonyforming bone marrow cells from patients with aplastic anemia[J], Exp Hematol 1997; 25: 573～81.
[57] Guadalupe Mart'nez-Jaramillo, Eugenia Flores-Figueroa, Elizabeth Sánchez-Valle, et al. Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia[J]. Leukemia Research 2002; 26: 955～963
[58] Callera F, Falcao RP. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anemia [J]. Br J Haematol, 1997(1); 98: 18～20
[59] Callera F, Garcia AB, Falcao RP. Fas-mediated apoptosis with normol express of bcl-2 and p53 in lymphocytes from aplastic anemia[J]. Br J Haematol, 1998; 100(4): 698～703
[60] Craiy B, Hematopoietic cells from mice deficiemfin wild wild-typo P53 are more resistsnt to induction of apoptosis by some agents [J] SThompson Science, 1995; 267: 1459
[61] 奚永志，张双喜，郝秀娟．等．细胞凋亡调控蛋白在骨髓CD_(34)~+造血细胞中的表达[J]．中华医学杂志，1997：77(3)：197～200
[62] Maciejewski JP, Selleri C, Sato J, et al Increased apoptosis in aplastic anemia bone marrow, progenitor cells [J]. Br J Haematol, 1995; 91 (1): 245～52
[63] Horikawa K, Nakakuma H, Kawaguchi T, et al Characterization and partial purification of human marrowy cells capable of initiaing long-term hematpoiesis in vitro[J]. Blood, 1997; 90: 2716
[64] 夏长青．李景斗．储榆林．再生障碍性贫血免疫治疗现状[J]．国外医学 内科学分册．1997；24：338～341
[65] 宋振岚，谢普耀．范成明，等．再生障碍性贫血免疫发病机制的探讨[J]．中华血液学杂志，1996：17[4]：173～175
[66] Viale M ,Merli A,Bacigalupo A. Analysis at the clonal level of T-cell phenotype and functions in severe aplastic anemia patients[J]. Blood, 1991, 81: (6)1268～1274
[67] Nakao S. Immunc mechanism of aplastic anemia [J]. Int J Haematol, 1997, 66 (2): 127～134
[68] Melenhorst J J, Krieken J H, Dreef E, et al. T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anemia[J]. Br J Haematol, 1997;99:517
[69] 夏长青，储榆林．张君奎，等．严重型再生障碍性贫血患者骨髓和外周血HLA-DR~+T细胞的变化及其淋巴细胞造血抑制活性的研究[J]．中华血液学杂志，1997；18[4]：186～189
[70] Melenhorst JJ, Fibbe WE, Struyk L, et al. Analysis of T-cell clonality in bone marrow of patients with acquired aplastic anaemia[J]. Br J Hacematol. 1997, 96: 85～91
[71] 王冠军．再生障碍性贫血病人骨髓及外周血T淋巴细胞亚群与造血抑制的关系[J]．中华内科杂志．1990；13[4]：229～230
[72] Nagasawa T, Hasegawa Y, Shimizu S. et al .Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects[J], Br J Hematol 1998; 101: 242
[73] 夏长青．储榆林．邵宗鸿．等．严重型再生障碍性贫血患者骨髓造血祖细胞集落的形成与免疫抑制治疗疗效的关系[J]．中华血液学杂志．1997；18[11]：542～543
[74] Nistico A.Yaoung ns. Gamma-interferon gone expression in the marrow of patients with aplastic anenmia [J]. Ann intem Med. 1994; 120:463～469
[75] Nakao S, Yamaguchi M, Shiobara S, et al. Interferon-r gene expression in unstimulatated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia[J]. Blood. 1992; 79 2532～2535
[76] 曾风华，沈柏均，时庆，等．再生障碍性贫血忠者骨髓T淋巴细胞的研究[J]．中华血液学杂志，1997：18[11]：542～543
[77] Manz CY, Dietrich PY, Schnuriger V, et al. T-cell receptor β chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia[J]. Blood Cells Mol and Dis, 1997; 23: 110～122
[78] Nimer SD, Ireland P, Meshikinpour AP, et al. An increased HLA DR2 frequency is seen in aplastic anemia patients [J]. Blood, 1994; 84: 923～927
[79] Nakao S, Takamatsu H, Chuhjo T, et al .Identification of a specific HLA class Ⅱ haplo type strongly associated with susceptibility to cyclosporiue-dcpendent aplastic anemia[J]. Blood, 1994; 84: 4257～4261
[80] 张学光，傅晋翔．再生障碍性贫血免疫机制的研究进展[J]．中国免疫学杂
志．2000：16(10)：517～520
[81] Nakao S, Takamatsu H, Yachie A, et al. Establishment of a CD4+ Tcell clone recognizing autologous hematpopietic progenitor cells from a patient with immune-mediated aplastic anemia [J]. Exp Hematol. 1995; 23: 433～438
[82] Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRBl *0405-restrcticted cytotoxicity for hematopoietic cells in a paeent with aplastic anemia[J]. Blood, 1997; 89: 3691～3699
[83] 赵劲秋，王燕婷，邵念贤．等．再生障碍性贫血T细胞亚群及NK细胞活性与疗效的关系[J]．上海免疫学杂志．1996：18[4]：232～234
[84] 郑以州，储榆林．ALG／ATG治疗再生障碍性贫血疗效机制研究进展[J]．国外医学 内科学分册．1997；24[4]：206～208
[85] 邵宗鸿，陈克其．陈桂彬，等．严重型再障患者血清 IL-2、sIL-2R 水平与免疫抑制治疗关系的研究[J]．中华血液学杂志．1997；18[3]：180～182
[86] Koijima S. Hematopoietic growth factors and marrow stroma in aplastic anemia [J]. Int J Hematol. 1998, 68: 19～28.
[87] Stark R, et al Acquired aplastic anemia [J]. Blood, 1995; 85: 645
[88] Fujiwara M. Grenulocyfe colony-stimalating factor and granulocyte [J] Acta Haematol Jpn, 1990; 75: 421
[89] Gibson FM, et al Erythropoietin and platelet production[J]. Br J Haematol, 1995; 91(8):551～561
[90] Stark R, et al. Cytokine gene expression in peripheral bloodmononudear cells during graft-versus-host disease after allogenic bone marrow transplantation[J]. Br J Haematol, 1993;83(11):560～566
[91] Nissen C Wodnar -Filipowicz A, Slanicka-Krieger M, et al[J]. Eur J Haematol, 1995; 55 (6): 255～61.
[92] Holmberg L, Seidel K, Leisenring W, et al Cyclosporin A in aplastic anemia report a workshop[J]. Blood, 1994; 84(11): 3685～90
[93] 刘杰文．齐淑玲．de Wynter E，et al．长期培养的人骨髓基质细胞中有关造血调节的粘附蛋白表达的研究．中华血液学杂志．1997：18[8]：468～469
[94] 陈文杰，朱平．血液分子生物学 第一版 北京：中国医药科技出版社1993：49～51
[95] Radera G, Petrocelli T, Behrend E, et al. Overexpression of the
Integrin-linked kinase promotes anchorage independent cell cycle progression[J]. J Biol Chem 1997; 272(21): 13937～13944
[96] 董凌莉，刘文励，孙汉英，等．川芎嗪对再生障碍性贫血小鼠细胞粘附作用研究[J]．中华血液学杂志，1999；20[4]：178～179
[97] 董爱英，王润田．马立人．20 例再生障碍性贫血的细胞因子和粘附分子的表达分析[J]．中华检验医学杂志，2002；23[5]：156～158
[98]金朝晖，陶英，杨梅如．等．细胞间粘附分子在急性髓系白血病骨髓切片中的表达及临床意义[J]．中国实用内科杂志．2000：20(6)：346～348
[99] Wodnar-Filipowicz A, Yancik S, Moser Y, et al. Levels of soluble stem cell factor in serum of patients with aplastic anemia[J]. Blood 81:3259～3264, 1993.
[100] Nimer SD, Leung DHY, Wolin MJ. Golde DW. Serum stem cell factor levels in patients with aplastic anemia[J]. Int J Hematol 1994: 60: 185～189
[101] Kojima S, Matsuyama T, Kodera Y. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anemia [J]. Br J Haematol, 1997; 99(2):440～446
[102] 傅晋翔．张宏．虞斐 张学光．再生障碍性贫血正负造血生长因子浓度变化及临床意义[J]．中国免疫学杂志．2000：(16) 10：554～557
[103] Ronald L. Paquette , Nicholas C. Hsu , H. Phillip Koeffler. Analysis of c-kit Gene Integrity in Aplastic Anemia|J|. Blood Cells, Molecules, and Diseases 1996; 22 (14): 159～168
[104] 邵宗鸿，陈桂彬．张泓．等．再生障碍性贫血忠者骨髓造血干／祖细胞c-kit受体表达[J]．中华血液学杂志．1999：20 (10)：532～534
[105] Wodnar-Filipowicz A, Ticheili A, Zscbo KM, Speck B, Nissen C. Stem cell factor stimulates the in vitro growth of bone marrow cells from aplastic anemia patients[J]. Blood 1992; 79: 3196～3202
[106] Bagnara GP, Strippoli P, Bonsi L, et al. Effect of stem cell factor on colony growth from acquired and constitutional (Fanconi) aplastic anemia[J]. Blood 1992: 80:382～387
[107] [110] Aiuti A, Webb IJ, Bleul C. et al. The chemokine SDF-1 is a chemoattractant for human CD_(34)~+ hcmatopoictic progenitor cells and provides a new mechanism to explain the mobilization of CD_(34)~+ progenitors to peripheral blood[J].
J Exp Med, 1997,185:111～120
[108] Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor[J]. Science, 1996, 272～276
[109] D'Apuzzo M, Rolink A, Loetscher M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4[J]. Eur J Immunol, 1997, 27: 1788～1794
[110] Sozzani S, Liuni W, Borsatti A, et al. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines[J]. J Immunol, 1997, 159: 1993-2000
[111] Mohle R, Bautz F, Rafii, S, et al. The chemokine receptor CXCR4 is expressed on CD_(34)~+ hematopoietic progenitors and leukemic cells and mediated transendothelial migration induced by stromal cell-derived factor-1[J]. Blood, 1998, 91: 4523～4530
[112] Tsuge I, Kojima S, Matsuoka H, et al Blood cell cytoadhesion molecules[J]. Br J Haematol, 1993; 84(1):137～43
[113] 第七届全国再生障碍性贫血学术会议纪要[J] Chinese Journal of Haematology，April 1996，vol 17．No．4
[114] 张之南主编．血液病诊断及疗效标准．天津：天津科学技术出版社，1991：31～34
[115] 杨天楹主编．造血细胞培养技术．西安：陕西科学技术出版社 1985：147-160
[116] 储榆林．再生障碍性贫血几种常见治疗药物评价[J]．临床血液学杂志，2000：13(3)：139～140
[117] 孙伟正，等．以补肾中药为主治疗再生障碍性贫血215例的生存率及远期疗效分析[J]．中医杂志，1988；29(4)：27
[118] 曲佳丽．黑龙江中医药大学93年博士论文，1993；3
[119] 薄红，刘传瑞．范东明．等．补髓生血颗粒对慢性再生障碍性贫血患者红细胞免疫功能、血清CIC、补体C3的作用[J] 中国中医药科技．1999：6(2)：101
[120] 孙伟正，王样琪，袁斌华．等 应用“补髓生血颗粒”治疗24例慢性再生障碍性贫血骨髓 CD34、CD 10变化规律的分析[J]中医药信息．1994；11(2)：28～30
[121] 朱跃岚．孙伟正．补髓生血胶囊治疗慢性再生障碍性贫血临床研究[J]北京
中医药大学学报，1998：21(5)：48～49
[122] 赵新广，王样麒．朱跃岚，等．补髓生血胶囊对慢性再障患者造血干／祖细胞作用的实验研究[J]中医药信息．1998：(153)：53～55
[123] 孙伟正，罗梅宏．李海霞．等．补髓生血颗粒对慢性再生障碍性贫血患者血清可溶性Fas、肿瘤坏死因子、白细胞介素2表达作用的影响[J] 中医杂志，2001： 42(9)：546～547
[124] 孙伟正．罗梅宏，蒋宁，等．补髓生血颗粒对慢性再生障碍性贫血患者血清Fas、Bcl-2表达作用[J] 中国实验方剂学杂志．2001：7(4)：54～55
[125] 补髓生血颗粒对慢性再生障碍性贫血患者 CD34+、Fas+及CD34+mP53表达细胞影响的实验研究[J] 中医药学报，2001：29(4)：36-37
[126] Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractans: stromal cell-derived factor-1, steel factor, and the bone marrow environment[J]. Blood, 1998, 91 (1): 100～110 al analysis of bone marrow progenitor cell [J]. Blood, 1995, 16(12): 619～622
[127] 李夏新，洪平．曾琼．血小板内皮粘刚因子对脐血造血细胞的影响[J]第一军医大学学报，1999：19(1)：15～17
[128] 金朝辉．骨髓活检塑料包埋技术加强新进展[J]．医学综述．1999，10(5)： 186～188
[129] Verfaillie C, et al. Differentiation of primitive human multipotent hemopoietic progenitors into single lineage clonogenic progenitors is accompanied by alteraions in their interaction with fibronectin [J]. J Exp Med, 1991, 174: 693
[130] Verfaillie C, et al. Direct contct between progenitors and stroma is not requireds for human in vitro hematopoiesis[J]. Blood ,1992, 79: 2821
[131] Quesenberry P J, Crittenden R B, Lowry P, et al In. vivo studies of stromal niches[J]. Blood Cells. 1994, 20: 97